Klaus Gottlieb, MD, FACG, has joined Synthetic Biologics as its vice president of clinical and regulatory affairs.
Prior to joining Synthetic Biologics, Dr. Gottlieb was the senior medical director of therapeutic strategy – gastroenterology at Fortune 500 company Quintiles, according to the report.
Dr. Gottlieb will provide further leadership support as Synthetic Biologics moves forward with Phase 2 clinical trials for its irritable bowel syndrome and Clostridium difficile products.
He will report directly to Joseph Sliman, MD, MPH, senior vice president of clinical and regulatory affairs.